Payment overview · 2025
General Payments
$854.40
38 reported records · 14 companies
Healthcare provider profile · identity verified
Sheila Sagar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1104847896
Verified facts
What the public records show
CMS Open Payments records show Sheila Sagar, M.D. received $854.40 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Otezla, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.40 | 19.0% | 10 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $150.00 | 17.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.02 | 9.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.52 | 8.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.25 | 7.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.49 | 6.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.38 | 6.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.65 | 5.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.32 | 4.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.87 | 4.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.34 | 3.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.11 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.12 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.93 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $854.40 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $162.40 | 10 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.07 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.07 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.25 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.38 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.65 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $44.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.08 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 948 | 220 |
| Amlodipine Besylate | Amlodipine Besylate | 743 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 724 | 194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 560 | 143 |
| Alprazolam | Alprazolam | 476 | 96 |
| Losartan Potassium | Losartan Potassium | 465 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 453 | 110 |
| Lisinopril | Lisinopril | 420 | 109 |
| Omeprazole | Omeprazole | 409 | 107 |
| Gabapentin | Gabapentin | 393 | 95 |
| Simvastatin | Simvastatin | 372 | 82 |
| Furosemide | Furosemide | 323 | 95 |
| Eliquis | Apixaban | 293 | 57 |
| Metformin Hcl | Metformin Hcl | 290 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 71 |
| Trazodone Hcl | Trazodone Hcl | 270 | 61 |
| Sertraline Hcl | Sertraline Hcl | 263 | 60 |
| Donepezil Hcl | Donepezil Hcl | 262 | 58 |
| Memantine Hcl | Memantine Hcl | 254 | 49 |
| Potassium Chloride | Potassium Chloride | 241 | 63 |
| Buspirone Hcl | Buspirone Hcl | 234 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 227 | 53 |
| Tramadol Hcl | Tramadol Hcl | 226 | 55 |
| Lorazepam | Lorazepam | 213 | 47 |
| Allopurinol | Allopurinol | 204 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 45 |
| Carvedilol | Carvedilol | 185 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 51 |
| Famotidine | Famotidine | 176 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 29 |
| Spironolactone | Spironolactone | 162 | 43 |
| Meloxicam | Meloxicam | 160 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 31 |
| Mirtazapine | Mirtazapine | 142 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 133 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 47 |
| Xarelto | Rivaroxaban | 126 | 27 |
| Risperidone | Risperidone | 121 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 34 |
| Ozempic | Semaglutide | 110 | 25 |
| Atenolol | Atenolol | 107 | 26 |
| Midodrine Hcl | Midodrine Hcl | 104 | 23 |
| Montelukast Sodium | Montelukast Sodium | 104 | 25 |
| Divalproex Sodium | Divalproex Sodium | 99 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 33 |
| Temazepam | Temazepam | 91 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 16 |
| Azithromycin | Azithromycin | 84 | 71 |
| Lovastatin | Lovastatin | 84 | 21 |
| Glimepiride | Glimepiride | 83 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 17 |
| Ezetimibe | Ezetimibe | 79 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 28 |
| Methenamine Hippurate | Methenamine Hippurate | 77 | 15 |
| Pregabalin | Pregabalin | 77 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 32 |
| Mounjaro | Tirzepatide | 70 | 17 |
| Celecoxib | Celecoxib | 69 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 69 | 16 |
| Cephalexin | Cephalexin | 66 | 32 |
| Metformin Hcl Er | Metformin Hcl | 66 | 22 |
| Prednisone | Prednisone | 66 | 43 |
| Clonidine Hcl | Clonidine Hcl | 64 | 18 |
| Alendronate Sodium | Alendronate Sodium | 63 | 20 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Diazepam | Diazepam | 63 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 26 |
| Methylprednisolone | Methylprednisolone | 62 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 22 |
| Aripiprazole | Aripiprazole | 59 | 13 |
| Synthroid | Levothyroxine Sodium | 59 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 35 |
| Baclofen | Baclofen | 56 | suppressed |
| Bumetanide | Bumetanide | 56 | 15 |
| Farxiga | Dapagliflozin Propanediol | 56 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 49 |
| Latanoprost | Latanoprost | 55 | 12 |
| Oxcarbazepine | Oxcarbazepine | 55 | suppressed |
| Estradiol | Estradiol | 54 | 23 |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 16 |
| Valsartan | Valsartan | 50 | 15 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Topiramate | Topiramate | 48 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 11 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Telmisartan | Telmisartan | 37 | 11 |
| Terazosin Hcl | Terazosin Hcl | 37 | 13 |
| Finasteride | Finasteride | 35 | 12 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | 12 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 25 |
| Gemtesa | Vibegron | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 24 |
| Torsemide | Torsemide | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 13 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 17 |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 22 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 12 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | 11 |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Methimazole | Methimazole | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Safetyglide Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $854.40 · 38 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Filspari, General - Pain Management, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error